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Abstract
Background: Brain stereotactic biopsy (SB) followed by conventional histopathology and immunohistochemistry
(IHC) is the gold standard approach for primary central nervous system lymphoma (PCNSL) diagnosis. Flow
cytometry (FCM) characterization of fine-needle aspiration cytology and core needle biopsies are increasingly
utilized to diagnose lymphomas however, no biological data have been published on FCM characterization of fresh
single cell suspension from PCNSL SB. The aim of this study was to establish the feasibility and utility of FCM for the
diagnosis and characterization of brain lymphomas from a tissue samples obtained by a single SB disaggregation.
Methods: Twenty-nine patients with a magnetic resonance suggestive for PCNSL entered the study. A median of 6
SB were performed for each patient. A cell suspension generated from manual tissue disaggregation of a single,
unfixed, brain SB, was characterized by FCM. The FCM versus standard approach was prospectively compared.
Results: FCM and IHC showed an high degree of agreement (89 %) in brain lymphoma identification. By FCM, 16
out of 18 PCNSL were identified within 2 h from biopsy. All were of B cell type, with a heterogeneous CD20 mean
fluorescence intensity (MFI), CD10 positive in 3 cases (19 %) with surface Ig light chain restriction documented in 11
cases (69 %). No false positive lymphomas cases were observed. Up to 38 % of the brain leukocyte population
consisted of CD8 reactive T cells, in contrast with the CD4 positive lymphocytes of the peripheral blood samples
(P < 0.001). By histopathology, 18 B-PCNSL, only one CD10 positive (5 %), 1 primitive neuroectodermal tumor (PNET)
and 10 gliomas were diagnosed. A median of 6 days was required for IHC diagnosis.
Conclusion: Complementary to histopathology FCM can contribute to a better characterization of PCNSL, although
necrosis and previous steroid treatment can represent a pitfall of this approach. A single brain SB is a valid source
for accurate FCM characterization of both lymphoma and reactive lymphocyte population, routinely applicable for
antigen intensity quantification and consistently documenting an active mechanism of reactive CD8 T-lymphocytes
migration in brain lymphomas. Moreover, FCM confirmed to be more sensitive than IHC for the identification of
selected markers.
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Background
Primary central nervous system lymphoma (PCNSL), a rare
hematological disease, represents a big challenge for clini-
cians and researchers [1, 2]. Despite improved therapeutic
approaches, the diagnostic - prognostic characterization
has documented little improvement and long-term re-
sponse to treatment is rare [3, 4]. More than 90 % are dif-
fuse large B-cell lymphomas (DLBCL) derived from a late
germinal center B cell [5]. PCNSL is usually a widespread -
diffusely infiltrating lymphoma. Thereafter, efforts at resec-
tion are discouraged, although resection may be associated
with prolonged survival in surgically safe, single, PCNSL le-
sions [6]. Hence, stereotactic biopsy (SB) followed by con-
ventional histopathology and immunohistochemistry (IHC)
is the gold standard diagnostic approach useful to perform
a differential diagnosis among other brain lesions, such us
gliomas [7–11].
Flow cytometry (FCM) is a proven valuable diagnostic
tool for the diagnosis and monitoring of hematological
malignancies in routine clinical practice [12, 13]. More
recently, FCM immunophenotype of fine-needle aspir-
ation and/or core needle biopsy from lymphoid tissues
has shown to improve diagnostic accuracy in B-cell non-
Hodgkin lymphomas classification [14–18] and FCM
significantly increases the sensitivity and specificity of
cerebrospinal fluid (CSF) infiltration detection in onco-
hematology [19–22]. However, no biological data have been
published on FCM immunophenotype of fresh single-cell
suspension obtained from SB of brain lymphomas.
We performed a feasibility study to evaluate the diag-
nostic and potential added value of FCM characterization
of a single SB taken in vivo from intra-cerebral suspected
lymphomas. FCM was compared with conventional IHC
results in terms of diagnosis reliability and sensitivity in
cell markers identification. The membrane CD20 mean
fluorescence intensity (MFI) was evaluated to document,
in PCNSL, the intensity of expression of a surface mol-
ecule potentially related to clinical response to Rituximab
[23]. Finally, the tumor lymphoid side-population was
characterized and compared to the peripheral blood (PB)
lymphocytes phenotype, to investigate the blood-brain




Twenty-nine patients who underwent diagnostic SB for
CNS tumor at Regina Elena National Cancer Institute
were evaluated. All cases entered the study because of a
magnetic resonance suggestive for PCNSL. About 50 %
of enrolled patients underwent a previous steroid treat-
ment to limit the mass-related cerebral edema before
SB. The study was approved by our Institutional Ethics
Committee and a signed informed consent was obtained
from all the patients.
Contrast-enhanced magnetic resonance
Magnetic Resonance Imaging (MRI) was performed on a
1.5-T system (Optima MR 450w, GE Health-care,
Milwaukee, Wisconsin) with dedicated 16-channels
receive-only RF coils; slice thickness 3 mm and matrix
size of 512 × 512 were used. Before contrast medium in-
fusion Spin-echo (SE) sequences T1, T2 and FLAIR in
axial (T1, T2 e FLAIR) e cornal (T2) planes were per-
formed. After contrast medium infusion (0.1 mmol/Kg
body weight of gadopentetate dimeglumine contrast agent
was administered intravenously, at a rate of 2 ml/s.) a volu-
metric contrast-enhanced T1-weighted GRE sequence was
obtained (TR/TE = 7.8 ms/3.2 ms, matrix size = 512 × 512,
voxel size = 0.5 x 0.5x 0.5 mm3) in axial plane with a recon-
struction in coronal and sagittal planes to obtain very thin
section with fat-suppressed images. Diffusion Imaging
(DWIs) were obtained by single-shot SE EPI using two b
value (0-1000).
The MRI criteria for subject inclusion into the study
were: 1) single or multiple lesions with periventricular
sites; 2) low signal intensity on T2 weighted sequences; 3)
homogeneously enhancement mass; 4) marked oedema; 5)
hyperintense on DWI and hypointense on ADC maps; 6)
enhancement of cranial nerve with increase nerve diam-
eter [10] (Fig. 1). The MRI findings were evaluated by two
neuroradiologists with 20 and 10 years of experience,
respectively.
Flow cytometry on brain stereotactic needle biopsy
Brain SB were performed using the Cosman-Roberts-
Wells frame (Radionics, Burlington, Massachusetts). A
median of 6 (range 5-8) tissue biopsies, with a medium
size of 1 x 10 mm, were obtained. Immediately after ex-
traction, each specimen was fixed with formalin for
pathological evaluation and one biopsy was collected in
a tube without any transport medium for FCM analysis.
The cell suspension was generated from a single,
unfixed, SB fragment by gentle manual disaggregation in
a sterile Petri dish containing 2-4 ml of phosphate buff-
ered saline (PBS, Gibco by Life Technologies, UK) using
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a 10-mL syringe plunger rod. The released cells were
collected and washed twice in PBS for 5 min at 1600
revolutions per minute. The supernatant was discarded
and the pellet of cells was suspended in PBS and stained,
according to the manufacturer’s recommendations, using a
6-colour panel of antibodies (Fitc/PE/PerCP/PE-Cy7/APC/
APC-Cy7) and the “Duo-lyse” program of the Becton
Dickinson Bioscience (BDB) Lyse-Wash-Assistant accord-
ing to the following combinations: 1) CD3/CD56/CD45/
CD4/CD19/CD8; 2) CD5/CD10/CD45/CD2/CD79b/CD20;
3) surface immunoglobulin (sIg) Ig lambda/sIg kappa/
CD45/CD34/CD22/CD14, all from Becton Dickinson Bio-
science (BDB). The FCM characterization was performed
within 1 to 2 h from biopsy. The whole volume of sample
was acquired and analyzed using a BDB FACSCanto flow
cytometer and BDB theFACSDiva software.
The CD45 positive cells were gated and the percentage
of B, T and myeloid population were evaluated. Surface
Ig light chain expression was evaluated on the CD22
positive population; CD4 and CD8 expression was evalu-
ated as the percentage of total CD3 positive lympho-
cytes. The markers expression was reported as
percentage of positive cells within the CD45 positive
population. The reactive population of small lympho-
cytes was utilized as positive/negative internal control.
The MFI ratio for the CD20 antigen was calculated by
comparison with negative control. An immunoperoxi-
dase technique on fixed cytospins was utilized to investi-
gate the presence of intra-cytoplasmic Ig light chains
expression in the surface negative cases, as previously
described [24].
Immunofenotype was also performed on CSF samples
of 5 PCNSL cases. A volume of 3.5 mL (range 2.8-10) of
CSF was collected in a tube without any transport
medium and processed within a few (1-3) hours from
collection to minimize cell loss.
Flow cytometry on peripheral blood samples
The peripheral blood T/NK lymphocytes subset was
evaluated by FCM according to the following combin-
ation: CD3/CD56/CD45/CD4/CD19/CD8. The lympho-
cytes phenotype was evaluated gating on the CD45
bright lymphoid cells. The CD4 and CD8 subset was
evaluated on the percentage of total CD3 positive T
lymphocytes.
Histopathology
All tumors were classified according to the World
Health Organization (WHO) classification [25] by con-
ventional histology (H&E) and IHC on formalin-fixed,
paraffin embedded SB tissue, utilizing the following
antibodies: CD20, CD10 (clone 56C6), CD138, CD5,
(Novocastra, Menarini, Florence, Italy), CD3, CD45
(CLA), CD79a, Ki-67, CD34 (QBEND clone), CD68 (KP1)
p53 and GFAP (Dako Milan, Italy), CD56 (NCAM) (UCS
Diagnostic, Rome, Italy) by a streptavidin-biotin enhanced
immunoperoxidase technique, according to the manufac-
turer’s recommendations. The study was conducted in
Fig. 1 MRI findings strongly suggestive for brain lymphoma: SE T2 sequences in coronal plane (a), diffusion in axial plane (b, c) and fat-suppressed T1
after contrast medium infusion in axial plane (d, e). MRI shows multiple bilateral, periventricula sites with low signal intensity on T2, with oedema,
hyperintensity signal on DWI and homogensously enhancement after contrast medium infusion
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double-blind, with the hematopathologists and the cytome-
trists not aware of each other’s interpretation.
Statistical analysis
Concordance analysis was performed to assess the de-
gree of agreement (concordance) between FCM and IHC
in PCNSL diagnosis. Fisher’s exact test was conducted to




Twenty-nine patients entered the study. The median age
was 60 years (range 14–81), 16 patients were male and
13 female; all were HIV negative.
Histopathology
Eighteen PCNSL, 1 primitive neuroectodermal tumor
(PNET) and 10 gliomas were diagnosed by histopath-
ology. By IHC, all PCNSL were CD45 CD20 CD79a
positive, CD34 negative, one case was CD10 positive
with a low intensity of expression, all with >70 % Ki-67
positive cells. A minority (5 to 10 %) of CD3 and CD5
reactive T lymphocytes scattered between the large
lymphoma B cells was documented in 17 cases. By con-
trast, more than 30 % of the leucocytes was represented
by a reactive perivascular T-cell infiltration (RPVI) in
one case, as confirmed by FCM (Table 1, case n° 2). In 2
cases a diffuse necrosis with a small residual foci of
lymphoma was documented by IHC. The PNET was
CD56/CD34 positive CD45 negative, with a significant
proportion of histiocytes and a minority of T lympho-
cytes among the tumor cells. The ten cases of gliomas
were histologically classified as high-grade and low-
grade in 8 and 2 cases, respectively. A median time of
6 days (5–8) was required between biopsy and diagnosis.
Brain stereotactic biopsy characterization by flow
cytometry
PCNSL markers expression
Sixteen out of 18 PCNSL (89 %) were identified by
FCM. Leukocyte population was characterized within
2 h from SB, with a median of 66059 (range 27870–
132550) CD45 positive cells and a proportion of 60 % to
96 % tumor B cells in all lymphomas (Table 1). Un-
equivocal identification of large lymphoma CD19 posi-
tive B cells (green color), CD3 small reactive T
lymphocytes (orange color) and CD45 negative CD56
positive brain/neuro-ectodermal cells (blue color) was
obtained in a single tube analysis (Fig. 2). All PCNSL were
CD19/CD22 positive, CD20 positive in 15/16 cases (92 %),
CD79b positive in 13/16 cases (81 %), CD5-CD34 negative,
with a surface Ig light chain restriction detected in 11 cases
(69 %), 7 Ig Kappa and 4 Ig Lambda light chain, respectively
(Table 1). No intra-cytoplasmic light chain expression
was documented by immunoperoxidase technique in
Table 1 Flow cytometry analysis of the CD45+ population in 16 PCNSL stereotactic biopsy shows a prevalence of large B cells sided
by reactive T lymphocytes and monocytes
N° % Large B Lymphoma Cells % Small reactive
T lymphocytes
% Myeloid cells






1 DLBCL 42864 75 70 1 2 3 10 8
2 DLBCL 44073 60 65 0 93 2 38 1
3 DLBCL 91746 65 61 0 2 1 18 9
4 DLBCL 78828 80 76 70 85 0 8 3
5 DLBCL 66480 85 0 0 0 0 11 1
6 DLBCL 91726 95 92 0 2 96 5 0
7 DLBCL 113162 96 93 0 90 0 1 3
8 DLBCL 132550 96 91 0 0 83 1 3
9 DLBCL 38657 96 89 0 97 0 3 1
10 DLBCL 55841 70 68 0 96 0 24 1
11 DLBCL 27870 81 78 0 96 1 20 3
12 DLBCL 85000 95 92 0 0 0 5 4
13 DLBCL 61640 77 70 95 95 0 21 4
14 DLBCL 72001 88 12 0 0 0 10 2
15 DLBCL 30660 88 10 83 0 97 10 2
16 DLBCL 49523 72 26 0 0 98 26 2
DLBCL diffuse large B-cell lymphoma
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the surface negative cases. Three cases were CD10
positive with surface Ig light chain restriction, consist-
ent with the germinal center origin of the lymphoma.
The CD20 expression was heterogeneous, with a me-
dian MFI ratio of 24.13 (range 7.55–58.55). One case
was CD20 negative by FCM and weak positive by
IHC. In 2 cases (11 %) FCM failed to identify a CNS
lymphoma. Focusing on the 2 brain lymphomas not
identified by FCM, a diffuse necrosis with a small re-
sidual foci of lymphoma was documented by IHC in
both cases. In one case, 4 out of 8 SB were negative
for PCNSL by IHC; in the second case, a prominent
necrosis (>50 % of the available tissue) was docu-
mented in all 8 biopsies evaluated by histopatology.
Both of failed cases occurred in patients who under-
went a previous steroid treatment.
Tumor-side population phenotype
From 1 % to 38 % of the leukocyte population was repre-
sented by CD2/CD3/CD5 positive reactive T lymphocytes
with a prevalence of CD8 positive cells documented in 13/
16 PCNSL cases (81 %) and more than 40 % of CD56
positive T cells in two (Table 2, cases n°1 and n°14). A
minority (<10 %) of CD4 dim CD14 positive monocytes
among the lymphoma cells was also documented.
PCNSL negative cases
A prevalence of CD45 negative, CD56 positive cells,
consistent with a population of neuro-ectodermal origin,
was identified in 13 cases, flanked by a minority of CD3
positive reactive T lymphocytes. In the PNET case, a
prevalence (70 %) of CD45 negative, CD56/CD34 posi-
tive cells was documented flanked by a population of
CD45/CD4dim/CD14 positive monocytes and CD4 re-
active T lymphocytes.
Comparing FCM with IHC by concordance analysis, a
statistically significant agreement (P = 0.0034) with a
Cohen’s kappa coefficient of 0.859 was found.
CSF flow cytometry of PCNSL cases
Lumbar puncture yielded adequate material for FCM
analysis in all the cases analyzed. The CSF samples had a
median cell count of 3 cell/μL (range 1-5). Despite the
low CSF absolute cell number, a median of 6229 (range
1436-8285) evaluable cells were analyzed. The cell popu-
lation was represented by a prevalence of CD4 positive
T lymphocytes (76 %; range 65–93) in all the cases,
Fig. 2 Flow cytometry analysis of cell suspension from one brain stereotactic needle biopsy of PCNSL. Blue color has been utilized to mark CD56
positive/CD45 negative brain cells (a, b, d), green for CD10 CD19 CD20 sIg-Kappa light chain positive large lymphoma cells (c, e, f), orange for
the side population of CD3 positive T lymphocytes (a, b, c)
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sided by monocytes (CD14 positive = 6 %; range 1–13).
In one case, despite the low cell count (1 cell/μL), 30 %
of the lymphoid population was represented by clonal B
cell, CD19 CD20 CD22 positive, CD5 CD10 negative,
with surface Ig lambda light chain restriction (case n°6).
Peripheral blood lymphoid asset
The peripheral blood T/NK lymphocytes subset was
evaluated on 10/16 PCNSL. A lymphocytopenia, 900
cell/μL (range 350–1800), was documented. In contrast
with the brain CD8 T lymphocytes prevalence (81 %), a
population of CD4 positive T cells was documented in 9/10
(90 %) PB samples (P < 0.001) (Table 2).
Discussion
This is a feasibility, prospective study that describes for
the first time the use of FCM applied on a cohort of
brain SB samples, providing evidence that a single SB is
a valid source for identification and characterization of
brain lymphomas and reactive infiltrating leucocytes,
with a significant agreement between the FCM and IHC
diagnosis (P = 0.0034). Despite the magnetic resonance
strongly suggestive for PCNSL in 29 selected cases, 18
PCNSL, 10 gliomas and 1 PNET were diagnosed by
IHC. FCM identified 16 out of 18 (89 %) PCNSL cases.
Thereafter, 2 brain lymphomas (11 %) were missed by
FCM. The overall experience indicates that FCM has
difficulty detecting high-grade lymphomas, particularly
DLBCL. Failure must be assigned to necrosis, cell fragil-
ity or inadequate sample size [15]. Moreover, necrosis
can represent a major problem in PCNSL diagnosis after
corticosteroid administration, as shown by a recently
published study [26], considering that a large portion of
newly diagnosed PCNSL patients often underwent a
steroid treatment just before diagnosis, for clinical need.
According to the study design, a single biopsy was ana-
lyzed by FCM while 6–8 samples were utilized for the
IHC characterization. Nevertheless, the manual process-
ing technique for tissue disaggregation allowed a suc-
cessful FCM identification of brain lymphomas in 89 %
of cases, confirming the limits of a correct diagnosis in
patients pre-treated with steroids. Our study shows that
a single SB is an adequate sample size for a comprehen-
sive PCNSL characterization in absence of tissue necro-
sis. In fact, in the 2 PCNSL cases not identified by FCM
the necrosis was the main factor. A diffuse necrosis with
a small residual foci of lymphoma was documented by
IHC in both cases, confirming the relevance of necrosis
in hampering the diagnosis in large cell lymphomas. It is
likely that performing FCM analysis on more than a sin-
gle bioptic sample the rate of success in FCM brain
lymphomas identification would increase.
FCM is a proven valuable diagnostic tool in
hematological CSF infiltration detection [27, 28], in-
creasing the sensitivity and specificity of leptomeningeal
disease identification in CNS lymphomas [22]. We have
recently documented that FCM can discriminate
between reactive and neoplastic plasma cells in CSF
samples with very low cell counts, confirming to be
significantly more sensitive than standard approaches
[21]. CSF FCM was performed on 5 out of 18 PCNSL
cases and, despite the low cell count, a clonal B cell
population was identified in one case. However, CSF
cytology was negative and, although FCM was indicative
Table 2 Flow cytometry analysis of the lymphoid T reactive population from 16 PCNSL SB and corresponding peripheral blood
samples
McAb % and CD4/CD8 ratio of reactive lymphocytes in SB and PB samples
Case n° 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Brain Streotactic Biopsy CD3 84 86 91 85 89 98 98 98 95 94 95 98 85 97 87 85
CD5 75 79 91 75 89 95 97 98 83 96 95 94 85 95 78 85
CD56 60 2 7 4 4 1 1 5 3 6 1 1 2 40 1 1
CD3/CD4 31 41 45 26 39 6 18 35 25 59 69 18 60 14 34 32
CD3/CD8 87 57 50 59 47 72 60 42 74 28 16 71 33 56 53 45
CD3/CD56 57 4 6 2 6 6 17 5 2 7 1 6 5 42 9 4
T4/T8 ratio 0.35 0.72 0.9 0.44 0.83 0.08 0.3 0.83 0.34 2.1 4.3 0.25 1.8 0.25 0.64 0.71
Peripheral blood samples CD19 nd nd nd 12 16 40 16 59 nd 29 19 15 nd nd 11 9
CD3 nd nd nd 64 63 48 55 16 nd 48 54 72 nd nd 69 89
CD56 nd nd nd 7 21 15 20 17 nd 23 25 20 nd nd 20 11
CD3/CD4 nd nd nd 73 59 50 79 66 nd 37 51 58 nd nd 53 57
CD3/CD8 nd nd nd 23 36 46 19 32 nd 62 47 38 nd nd 43 38
T4/T8 nd nd nd 3.17 1.6 1.08 4.15 2 nd 0.59 1.08 1.5 nd nd 1.23 1.5
nd not done
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of a B-cell clonal disorder, the data was not strong
enough to reach the diagnosis of PCNSL. These findings
are in agreement with previously published data [22].
A very wide panel of markers could be tested by FCM
in a single brain SB, FCM demonstrate to be more sensi-
tive than IHC for the identification of relevant markers.
CD10 has been reported to be 10 times lower in PCNSL
comparing to systemic diffuse large B-cell lymphomas
[29]. In our study, the CD10 expression was documented
in 3/16 PCNSL (19 %) by FCM and 1/18 (5 %) by IHC.
The reason for this discordance is uncertain. Probably
the different clones utilized for FCM (clone HI10a) and
IHC (clone 56C6) could be involved in this matter.
However, a different sensitivity between FCM and IHC
in antigen identification is widely documented. Our
report documents a possible underestimation of CD10
frequency of expression in PCNSL by IHC staining,
highlighting the added value provided by performing
FCM in terms of a more reliable technique for the iden-
tification of selected markers.
The panel of antigens used was in accordance with the
WHO guidelines [25]. However, more recently, a signifi-
cant differential expression of CD44 between Burkitt
lymphoma and CD10 DLBCL has been documented, mak-
ing CD44 an excellent candidate for rapid immunopheno-
typic discrimination between these two types of lymphoma
[30]. Flanking IHC studies, FCM characterization, enriched
by new relevant diagnostic markers, can significantly im-
prove the diagnostic approach to PCNSL.
Surface Ig light chain restriction was documented in
11 cases. Immunoglobulin light chains restriction is an
important adjunct to the use of surface markers in onco-
hematology [13]. However, light chain restriction is not
always documented on high grade B-cells NHL. In our
series 5 cases were both surface and intra-cytoplasmic
negative. Despite the lack of light chain restriction, the
high FSC/SSC scatter of the B cell population (large
cells) compared to the small T lymphocytes as well as
the prevalence of B cells (85 %, range 60-96) compared
to the T subset (10 %, range 1-38), strongly supported
the diagnosis of a B cell neoplasm, confirmed by histo-
pathology in all the cases. Moreover, since Ig light chain
expression in non-Hodgkin lymphomas (NHL) is diffi-
cult to identify by IHC, cytometry can easily represent
the method of choice for clonality detection in PCNSL.
The presence of a reactive immune response and peri-
vascular T-cell infiltrate within the lymphoma has been
shown to represent a prognostic biomarker and influ-
ence disease outcome in PCNSL [31, 32]. Antigen co-
expression, mandatory for the classification of T and NK
lymphocyte sub-populations, is easy to identity by FCM
while difficult to assess by IHC. In this study, we docu-
mented a significant difference in lymphocyte sub-set
distribution between brain lymphoma and peripheral
blood. A prevalence of CD8 reactive T lymphocytes was
documented in the majority (81 %) of PCNSL cases,
while a prevalence of CD4 positive lymphocytes was
identified in all but one peripheral blood samples (90 %)
(P < 0.001). CNS is an immunogical sanctuary with re-
stricted access and an unique microenvironment. The
present study consistently shows that the blood-brain
barrier actively selects a sub-population of CD8 non-
malignant cells in PCNSL, providing a promising ration-
ale for the investigation of cellular immunotherapy in
brain tumors. To date, there is an increasing interest in
engineered chimeric antigen receptor (CAR) T-cells in
hematologic malignancies, also in NHL [33]. In this
point of view, exploiting their migration to pathological
lesions, reactive T-cells could be used for adoptive im-
munotherapy strategies based, for example, on targeting
brain lymphoma CD19 positive B-cells by bi-specific T-
cell engager monoclonal antibodies or engineered CAR
T-cells in preclinical models.
Tumor associated macrophages, commonly present in
NHL, have been related to poor prognosis and are po-
tentially involved in the pathogenesis of brain NHL [34].
We identified a minority of CD4 dim CD14 positive
monocytes among the B lymphoma cells and a great
amount in the PNET case. Biological studies, aimed at a
better understanding of the role of the tumor associated
reactive population, would easily benefit from the FCM
approach.
The identification of new therapeutic strategies is
of prominent importance in PCNSL and FCM
characterization can be a valuable tool for the detection of
potential therapeutic targets and orientate tailored
antibody-based therapies. The CD20 B cell-specific anti-
gen is a membrane-bound protein whose expression is
very heterogeneous among different B lymphoma sub-
types [35] and significantly associated with disease prog-
nosis [36, 37]. This difference may correlate with clinical
response to Rituximab, a monoclonal antibody directed
against the CD20 antigen that, in combination with con-
ventional chemotherapy, has dramatically improved the
survival of patients with diffuse large B-cell lymphoma [3].
By contrast, reduced CD20 expression has been associated
with an inferior survival, suggesting that the evaluation of
cell surface antigen intensity of expression can improve
treatment tailoring of antibody-based therapy [38]. Anti-
CD20 antibody therapy has shown to improve disease
control and outcome in patients with primary CNS
lymphoma [23, 39]. No biological data, however, is avail-
able regarding the intensity of surface antigen expression
in intra-cranial B lymphomas. An objective quantification
of antigen intensity of expression can be easily performed
by FCM by the difference between antigen MFI and nega-
tive control. This technique is practical for use in routine
setting. Utilizing this approach, our study documents for
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the first time a marked variability between surface CD20
expression level in brain lymphomas, ranging from very
“bright” to “dim” in MFI with one CD20 negative case by
FCM. CD20 (L26) staining is not usually graded by pathol-
ogists, and hematopathologists report all lymphomas that
react with L26 antibody as “CD20 positive” regardless of
expression level [40]. Therefore, the determination of
CD20 MFI could represent a novel biomarker for a better
stratification of PCNSL patients more likely to benefit
from Rituximab treatment, for a more effective tailoring
of the first line therapy. Actually, this hypothesis should
be confirmed in further prospective studies. A prevalence
of CD45 negative CD56 positive cells, consistent with a
neuro-ectodermal population [41], was documented in 13
cases, with a strong CD34 expression identified in the
PNET case, suggesting a potential role of FCM in non
hematological tumors.
Conclusions
This paper provides evidence that a single brain stereotac-
tic core biopsy is a valid source for rapid identification and
accurate FCM characterization of CNS lymphomas. FCM
has shown to be more sensitive than IHC for selected
markers, easily applicable for antigen intensity quantifica-
tion and, documenting a prevalence of CD8 reactive T
lymphocytes in brain lymphomas, suggests an active
mechanism of lymphoid migration through the blood-
brain barrier, potentially providing relevant information
for further therapeutic decision making.
In the contest of the gold standard approach, the ad-
vantages of FCM over IHC include an excellent sensitiv-
ity, a short execution time, an objective quantification of
antigen intensity of expression, a reliable approach for
the evaluation of antigens co-expression on both tumor
and tumor-side populations. The presence of necrosis
remains a major disadvantage, as well as the require-
ment of fresh tissue for analysis. Finally, establishing a
provisional diagnosis of brain lymphoma, FCM could
positively affect the cost-benefit ratio, contributing in a
shortening of time-to-treat interval with reduction of
hospitalization indirect costs. Prospective studied will es-
tablish the synergic and complementary role of these
two techniques for a better diagnostic approach and
clinical management of brain lesions.
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